Chitosan Lactate Particles for Non-Compression Hemostasis on Hepatic Resection

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Surgical Innovation

Background:

• Massive liver bleeding from traumatic injury poses significant mortality risks.
• Effective hemostasis is crucial for managing liver trauma and preventing complications.
• Current hemostatic methods may have limitations in controlling severe liver hemorrhage.

Purpose of the Study:

• To develop novel non-compression hemostasis materials for traumatic liver bleeding.
• To evaluate the hemostatic efficacy and biocompatibility of chitosan lactate particles (CLP).
• To compare the performance of CLP against a commercial hemostatic agent.

Main Methods:

• Chitosan lactate particles (CLP) were synthesized as non-compression hemostasis materials.
• In vitro assessments included blood biocompatibility and antibacterial activity against S. aureus.
• In vivo hemostatic performance was evaluated in rodent and canine models of traumatic liver injury.

Main Results:

• CLP demonstrated excellent blood biocompatibility and antibacterial properties.
• CLP effectively promoted red blood cell and platelet adhesion, facilitating hemostasis.
• In vivo studies showed superior hemostatic performance of CLP compared to the commercial agent Celox™.

Conclusions:

• Chitosan lactate particles (CLP) represent a promising non-compression hemostatic material for traumatic liver injuries.
• CLP's ability to promote adhesion and its superior efficacy offer a significant advancement in bleeding control.
• These findings support the clinical potential of CLP in managing severe liver bleeding.